Sökning: id:"swepub:oai:gup.ub.gu.se/106623" >
A 24-week, multicen...
A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone
-
Newcomer, J. W. (författare)
-
Ratner, R. E. (författare)
-
- Eriksson, Jan W, 1959 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine,Lundberg Laboratory for Diabetes Research, Sahlgrenska University Hospital, Gothenburg, Sweden
-
visa fler...
-
Emsley, R. (författare)
-
Meulien, D. (författare)
-
Miller, F. (författare)
-
Leonova-Edlund, J. (författare)
-
Leong, R. W. (författare)
-
Brecher, M. (författare)
-
visa färre...
-
(creator_code:org_t)
- 2009
- 2009
- Engelska.
-
Ingår i: J Clin Psychiatry. - 1555-2101 .- 1555-2101 .- 0160-6689. ; 70:4, s. 487-99
- Relaterad länk:
-
http://www.ncbi.nlm....
-
visa fler...
-
https://gup.ub.gu.se...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- OBJECTIVE: This randomized, 24-week, flexible-dose study compared changes in glucose metabolism in patients with DSM-IV schizophrenia receiving initial exposure to olanzapine, quetiapine, or risperidone. METHOD: The hypothesized primary endpoint was change (baseline to week 24) in area under the curve (AUC) 0- to 2-hour plasma glucose values during an oral glucose tolerance test (OGTT); primary analysis: olanzapine versus quetiapine. Secondary endpoints included mean change in AUC 0- to 2-hour plasma insulin values, insulin sensitivity index, and fasting lipids. The first patient enrolled on April 29, 2004, and the last patient completed the study on October 24, 2005. RESULTS: Mean weight change (kg) over 24 weeks was +3.7 (quetiapine), +4.6 (olanzapine), and +3.6 (risperidone). Based on data from 395 patients (quetiapine, N = 115 [mean dose = 607.0 mg/day], olanzapine, N = 146 [mean dose = 15.2 mg/day], and risperidone, N = 134 [mean dose = 5.2 mg/day]), mean change in AUC 0- to 2-hour glucose value (mg/dL x h) at week 24 was significantly lower for quetiapine versus olanzapine (t = 1.98, df = 377, p = .048). Increases in AUC 0- to 2-hour glucose values were statistically significant with olanzapine (+21.9 mg/dL x h, 95% CI = 11.5 to 32.4 mg/dL x h) and risperidone (+18.8 mg/dL x h, 95% CI = 8.1 to 29.4 mg/dL x h), but not quetiapine (+9.1 mg/dL x h, 95% CI = -2.3 to 20.5 mg/dL x h). AUC 0- to 2-hour insulin values increased statistically significantly with olanzapine (+24.5%, 95% CI = 11.5% to 39.0%), but not with quetiapine or risperidone. Reductions in insulin sensitivity index were statistically significant with olanzapine (-19.1%, 95% CI = -27.9% to -9.3%) and risperidone (-15.8%, 95% CI = -25.1% to -5.4%), but not quetiapine. Total cholesterol and low-density lipoprotein levels increased statistically significantly with olanzapine (+21.1 mg/dL, 95% CI = 13.0 to 29.2 mg/dL, and +20.5 mg/dL, 95% CI = 13.8 to 27.1 mg/dL, respectively) and quetiapine (+13.1 mg/dL, 95% CI = 4.3 to 21.9 mg/dL, and +13.3 mg/dL, 95% CI = 6.1 to 20.5 mg/dL, respectively), but not risperidone. Statistically significant increases in triglycerides (+30.9 mg/dL, 95% CI = 10.9 to 51.0 mg/dL), total cholesterol/high-density lipoprotein (HDL) ratio (0.5, 95% CI = 0.2 to 0.8), and triglyceride/HDL ratio (0.3, 95% CI = 0.0 to 0.6) were observed with olanzapine only. CONCLUSION: The results indicate a significant difference in the change in glucose tolerance during 6 months' treatment with olanzapine versus quetiapine, with significant reductions on olanzapine and risperidone, but not quetiapine; these differential changes were largely explained by changes in insulin sensitivity. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00214578.
Nyckelord
- Adolescent
- Adult
- Aged
- Antipsychotic Agents/adverse effects/*therapeutic use
- Benzodiazepines/adverse effects/*therapeutic use
- Cholesterol
- HDL/blood
- Cholesterol
- LDL/blood
- Dibenzothiazepines/adverse effects/*therapeutic use
- Female
- Glucose/*metabolism
- Humans
- Insulin/blood
- Male
- Middle Aged
- Risperidone/adverse effects/*therapeutic use
- Schizophrenia/*drug therapy/*metabolism
- Triglycerides/blood
- Young Adult
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Newcomer, J. W.
-
Ratner, R. E.
-
Eriksson, Jan W, ...
-
Emsley, R.
-
Meulien, D.
-
Miller, F.
-
visa fler...
-
Leonova-Edlund, ...
-
Leong, R. W.
-
Brecher, M.
-
visa färre...
- Artiklar i publikationen
-
J Clin Psychiatr ...
- Av lärosätet
-
Göteborgs universitet
-
Uppsala universitet